Hospira’s Inflectra, EU’s First Biosimilar mAb, Will Challenge Skeptics
This article was originally published in The Pink Sheet Daily
Executive Summary
Hospira’s Inflectra becomes the first biosimilar monoclonal antibody to be authorized in Europe – but pricing and overcoming doctors’ skepticism looks like the key to real EU success.